Page 212 - HIV/AIDS Guidelines

Table 16b. Interactions between Non-Nucleoside Reverse Transcriptase Inhibitors*, Maraviroc,
Raltegravir, and Protease Inhibitors* (Page 2 of 3)

EFV ETR NVP RPV a MVC RAL

PK ↓ ETR possible ↓ ETR possible ↓ RPV possible MVC: AUC ↓ 53%, ETR: C min ↓ 17%
data C max ↓ 60% RAL: C min ↓ 34%

ETR Do not • Do not Do not MVC 600 mg BID Standard
coadminister. coadminister. coadminister. in the absence of a
Dose
potent CYP3A
inhibitor
With (FPV 1400 mg With (FPV 700 mg + With unboosted With boosted and Unknown; ↑ MVC No data
+ RTV 200 mg) once RTV 100 mg) BID FPV 1400 mg BID unboosted FPV possible
daily APV: AUC ↑ 69%, APV: AUC ↓ 33% ↑ RPV possible
PK APV: C min ↓ 36% C min ↑ 77% NVP: AUC ↑ 29%
data
With (FPV 700 mg
+ RTV 100 mg) BID
FPV
NVP: C min ↑ 22%
(FPV 1400 mg + RTV Do not coadminister (FPV 700 mg + RTV Standard MVC 150 mg BID Standard
300 mg) once daily with FPV +/− RTV. 100 mg) BID
Dose or (FPV 700 mg + NVP standard
RTV 100 mg) BID
EFV standard

With LPV/r tablets With LPV/r tablets With LPV/r RPV 150 mg once MVC: AUC ↑ ↓ RAL
c
500/125 mg BID + ETR: levels ↓ 30%– capsules daily with LPV/r 295% ↔ LPV/r
EFV 600 mg 45% (comparable to LPV: AUC ↓ 27% capsules
PK LPV levels similar to the decrease with and C min ↓51% LPV: no With LPV/r + EFV
data LPV/r 400/100 mg DRV/r) significant change MVC: AUC ↑
BID without EFV LPV: levels ↓ 13%– 153%
20% RPV: AUC ↑ 52%
LPV/r and C min ↑ 74%
LPV/r tablets Standard LPV/r tablets Standard MVC 150 mg BID Standard
c
c
500/125 mg BID; 500/125 mg BID;
LPV/r oral solution LPV/r oral solution
Dose
533/133 mg BID 533/133 mg BID
EFV standard NVP standard
NVP: no significant ↓ ETR possible ↓ RPV possible MVC: AUC ↔ and No data
PK change C ↑ 54%
data max
EFV: AUC ↓ 22%
Do not Do not coadminister. Do not Without PI Standard
NVP •
coadminister. coadminister. MVC 300 mg BID
Dose With PI (except
TPV/r)
MVC 150 mg BID
PK RAL: AUC ↓ 36% ETR: C min ↑ 17% No data No data RAL: AUC ↓ 37%
data RAL: C min ↓ 34% MVC: AUC ↓ 21%
RAL •
Dose Standard Standard No data No data Standard

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents K-42

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.